Civica taps Ned McCoy as new CEO

Civica, the hospital-backed generic pharmaceutical company, has tapped Ned McCoy as its new president and chief executive officer.

McCoy currently serves as Civica's chief operating officer and will succeed Martin VanTrieste as CEO on June 1.

VanTrieste will remain an advisor to the company and continue serving on Civica’s board of directors, the company announced. As part of the transition, McCoy will also join the board.

McCoy has been with Civica since the company launched in 2018. Civica is backed by some of the country's largest health systems as a way to address challenges with the supply and cost of frequently used drugs in hospitals. 

More than 55 health systems are Civica members, representing 1,550 U.S. hospitals and one-third of U.S. licensed beds. The company also added insurer Anthem to its membership in 2021.

McCoy has led efforts to secure manufacturing partnerships for over 60 sterile injectable medications that hospitals use daily.

He also has provided day-to-day oversight for Civica’s growing manufacturing efforts, including the building of Civica’s state-of-the-art essential medicines manufacturing facility in Petersburg, Virginia, expected to be operational in early 2024.

McCoy also helped orchestrate the partnership with Civica’s affordable insulin development partner, GeneSysBiologics, with the plan to bring Civica biosimilar insulins to market beginning in 2024.

Before Civica, McCoy served at Abbott for 32 years, where he led teams in hospital products, pharmaceutical products (now AbbVie), nutrition and corporate mergers and acquisitions. 

Most recently, Civica and its outpatient arm, CivicaScript, announced plans to develop, manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin beginning in 2024.

Dan Liljenquist, chairman of Civica's board of directors, said McCoy has a strong track record of leading companies to significant growth and executing complementary partnerships.

I am honored to serve as the next CEO of Civica and continue our pivotal work of delivering quality generic medications that are available and affordable to everyone," McCoy said. "Through much of my time at Civica, I have had the privilege of leading Civica’s operations, including helping to secure successful, long-term manufacturing partnerships and execute the building of our own manufacturing facility. I look forward continuing to work with our talented team and furthering our culture of innovation, excellence and dedication to improving patient lives with a new model for generic hospital and prescription medicines."

VanTrieste, a former Amgen executive, served as Civica's first CEO. 

“Martin’s decision to come out of retirement four years ago to help us shape and launch Civica was critical to bringing together diverse stakeholders to create a more reliable and affordable approach to generic medicines,” Liljenquist said. 

Civica is governed by leading hospital systems including CommonSpirit Health, HCA Healthcare, Intermountain Healthcare, Kaiser Permanente, Mayo Clinic, Memorial Hermann, Providence, SSM Health, and Trinity Health along with representatives of the payer community, such as Blue Cross of Idaho and Blue Cross Blue Shield Association and philanthropies committed to improving healthcare.